{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:56:17Z","timestamp":1781654177886,"version":"3.54.5"},"reference-count":48,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100001075","name":"Channel 7 Children\u2019s Research Foundation","doi-asserted-by":"publisher","award":["20\/13437316"],"award-info":[{"award-number":["20\/13437316"]}],"id":[{"id":"10.13039\/501100001075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Aust N Z J Psychiatry"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To determine the extent of cardiometabolic monitoring occurring in children\/adolescents 18\u2009years and under receiving antipsychotics in Australian general practice: study period 2011 to 2017.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Retrospective cohort study using large primary care database, MedicineInsight. Rates of monitoring within 12\u2009months of patients receiving an incident antipsychotic prescription were reported descriptively for weight, body mass index (BMI), waist circumference (WC), glucose, total cholesterol, triglycerides, high-density lipoproteins (HDL), blood pressure, liver function, prolactin, and metabolic syndrome (MetS) defined as weight, blood pressure and glucose. Target trial methodology was used to examine whether monitoring rates were higher in patients prescribed antipsychotics compared to patients not receiving antipsychotics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      55.9% of patients using antipsychotics were monitored at least once on at least one parameter. Weight was most frequently measured (39.1% patients measured at least once), followed by BMI (31.2%), blood pressure (29.0%), glucose (12.9%), liver function (9.1%), total cholesterol (8.1%), triglycerides (6.7%), HDL (3.1%), WC (1.6%) and prolactin (1.1%). Monitoring for MetS occurred at least once in 1.5% of patients. Antipsychotic users recorded a small but significantly higher rate of monitoring than non-users (1.157 vs 0.691 monitoring visits for any parameter within the 12\u2009month measurement period, difference 0.461; 95% CI [0.271, 0.660],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Rates of cardiometabolic monitoring were well below guideline recommendations. Our results suggest the need for education and training to increase awareness of adverse health impacts of antipsychotics and improve adherence to cardiometabolic guideline recommendations. Communication between primary and secondary health care providers also needs to be addressed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/00048674251361696","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T11:01:24Z","timestamp":1755082884000},"page":"824-834","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Cardiometabolic monitoring in children and adolescents prescribed antipsychotics in Australian primary care, 2011 to 2017"],"prefix":"10.1177","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9497-8752","authenticated-orcid":false,"given":"Julie","family":"Klau","sequence":"first","affiliation":[{"name":"Critical and Ethical Mental Health Research Group, Robinson Research Institute, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7153-2878","authenticated-orcid":false,"given":"David","family":"Gonzalez-Chica","sequence":"additional","affiliation":[{"name":"Discipline of General Practice, Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8781-6031","authenticated-orcid":false,"given":"Melissa","family":"Raven","sequence":"additional","affiliation":[{"name":"Critical and Ethical Mental Health Research Group, Robinson Research Institute, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8281-2878","authenticated-orcid":false,"given":"Natalie","family":"Aboustate","sequence":"additional","affiliation":[{"name":"Critical and Ethical Mental Health Research Group, Robinson Research Institute, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7585-2660","authenticated-orcid":false,"given":"Jon","family":"Jureidini","sequence":"additional","affiliation":[{"name":"Critical and Ethical Mental Health Research Group, Robinson Research Institute, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"e_1_3_3_2_1","unstructured":"American Academy of Child and Adolescent Psychiatry (2011) Practice parameter for the use of atypical antipsychotic medications in children and adolescents. Available at: www.aacap.org\/App_Themes\/AACAP\/docs\/practice_parameters\/Atypical_Antipsychotic_Medications_Web.pdf (accessed 23 November 2021)."},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1172559"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2022.0021"},{"key":"e_1_3_3_5_1","unstructured":"Australian Bureau of Statistics (2016) IRSAD: Index of relative socio-economic advantage and disadvantage. Available at: www.abs.gov.au\/ausstats\/abs@.nsf\/Lookup\/by%20Subject\/2033.0.55.001~2016~Main%20Features~IRSAD~20 (accessed 10 February 2020)."},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094112"},{"key":"e_1_3_3_7_1","article-title":"Data resource profile: MedicineInsight, an Australian national primary health care database","volume":"48","author":"Busingye D","year":"2019","unstructured":"Busingye D, Gianacas C, Pollack A, et al. (2019) Data resource profile: MedicineInsight, an Australian national primary health care database. International Journal of Epidemiology 48: 1741\u20131741h.","journal-title":"International Journal of Epidemiology"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0626-4"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1549"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10597-015-9833-0"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2017.0034"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2008.01.028"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.pra.0000435035.45308.03"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2015.21.9.769"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.2055-2335.2013.tb00252.x"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.4274\/jcrpe.v3i2.14"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32834a5bf6"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq439"},{"key":"e_1_3_3_19_1","first-page":"137","article-title":"Predictors of metabolic parameter monitoring in adolescents on antipsychotics in a primary care setting","volume":"9","author":"Ghate SR","year":"2012","unstructured":"Ghate SR, Porucznik CA, Said Q, et al. (2012) Predictors of metabolic parameter monitoring in adolescents on antipsychotics in a primary care setting. Mental Health in Family Medicine 9: 137\u2013148.","journal-title":"Mental Health in Family Medicine"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.2055-2335.2008.tb00787.x"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2017.07.001"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-021-06593-z"},{"key":"e_1_3_3_23_1","unstructured":"Health Education and Training Institute (HETI) (2014) Positive cardiometabolic health adolescent version: An early intervention framework for adolescents on psychotropic medication. Available at: www.heti.nsw.gov.au\/__data\/assets\/pdf_file\/0008\/449396\/adolescent_version_HETI_algorithm2014.pdf (accessed 25 July 2022)."},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.21383"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/0004867417691851"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/00048674211067720"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.005632"},{"key":"e_1_3_3_28_1","first-page":"660","article-title":"Second-generation antipsychotics in children: Risks and monitoring needs","volume":"64","author":"Lambert C","year":"2018","unstructured":"Lambert C, Panagiotopoulos C, Davidson J, et al. (2018) Second-generation antipsychotics in children: Risks and monitoring needs. Canadian Family Physician 64: 660\u2013662.","journal-title":"Canadian Family Physician"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2020.08.441"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2013.02.008"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/00048674211009620"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2021.0026"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000936"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpediatrics.2010.48"},{"key":"e_1_3_3_35_1","unstructured":"National Institute for Health and Care Excellence (2013) Psychosis and schizophrenia in children and young people: Recognition and management (Cg155). Available at: www.nice.org.uk\/guidance\/cg155 (accessed 4 June 2018)."},{"key":"e_1_3_3_36_1","unstructured":"NPS MedicineWise (2020) MedicineInsight data book version 3.0. Available at: www.nps.org.au\/assets\/NPS\/pdf\/MedicineInsight-databook-2020.pdf (accessed 2 August 2021)."},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2018.0013"},{"key":"e_1_3_3_38_1","first-page":"218","article-title":"Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth","volume":"20","author":"Pringsheim T","year":"2011","unstructured":"Pringsheim T, Panagiotopoulos C, Davidson J, et al. (2011) Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. Journal of the Canadian Academy of Child and Adolescent Psychiatry 20: 218\u2013233.","journal-title":"Journal of the Canadian Academy of Child and Adolescent Psychiatry"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.7.1132"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-2260"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/070674371205700504"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.0763"},{"key":"e_1_3_3_43_1","unstructured":"Scottish Intercollegiate Guidelines Network (2013) Management of schizophrenia: A national clinical guideline (SIGN 131). Available at: www.sign.ac.uk\/assets\/sign131.pdf (accessed 18 October 2018)."},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2016.0171"},{"key":"e_1_3_3_45_1","first-page":"1887","article-title":"Robust causal inference using directed acyclic graphs: The R package \u2018dagitty\u2019","volume":"45","author":"Textor J","year":"2016","unstructured":"Textor J, Van der Zander B, Gilthorpe MS, et al. (2016) Robust causal inference using directed acyclic graphs: The R package \u2018dagitty\u2019. International Journal of Epidemiology 45: 1887\u20131894.","journal-title":"International Journal of Epidemiology"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/10398560801958549"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/resp.12238"},{"key":"e_1_3_3_48_1","volume-title":"Antipsychotic Medication: Monitoring Adverse Effects When Prescribed for Children\/Adolescents, v1.2","author":"Women\u2019s and Children\u2019s Health Network (WCHN)","year":"2019","unstructured":"Women\u2019s and Children\u2019s Health Network (WCHN) (2019) Antipsychotic Medication: Monitoring Adverse Effects When Prescribed for Children\/Adolescents, v1.2. Adelaide, SA, Australia: Government of South Australia."},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5448.2007.00271.x"}],"container-title":["Australian &amp; New Zealand Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00048674251361696","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00048674251361696","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00048674251361696","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:58:09Z","timestamp":1777373889000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00048674251361696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1177\/00048674251361696"],"URL":"https:\/\/doi.org\/10.1177\/00048674251361696","relation":{},"ISSN":["0004-8674","1440-1614"],"issn-type":[{"value":"0004-8674","type":"print"},{"value":"1440-1614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]}}}